Categories Earnings, Health Care

Amgen’s (AMGN) Q4 results beat estimates

Amgen Inc. (NASDAQ: AMGN) topped revenue and earnings estimates for the fourth quarter of 2019. However, shares fell 2.7% in aftermarket hours as the outlook came below expectations.  

Total revenue fell 1% year-over-year to $6.2 billion, due to the impact of biosimilar and generic competition against select products, but surpassed expectations of $6.06 billion.   

Amgen topped Q4 revenue and earnings estimates

GAAP net income fell 12% to $1.7 billion while EPS dropped 5% to $2.85 hurt by higher operating expenses. Adjusted EPS rose 6% to $3.64, beating forecasts of $3.46.

Total product sales fell 2% year-over-year. During the quarter, sales for Prolia, Repatha, and Parsabiv increased double-digits driven by higher unit demand. Aimovig sales increased 3%.

Total operating expenses increased 8% in the quarter. R&D expenses rose 11% due to higher spending in research and early pipeline in support of oncology programs.

Also read: Western Digital Q2 2020 Earnings Snapshot

For full year 2020, total revenues are expected to be $25.0 billion to $25.6 billion. GAAP EPS is expected to be $10.85 to $11.65 while adjusted EPS is expected to be $14.85 to $15.60. Analysts had estimated adjusted EPS of $16.14 for the full year.

In December, the European Commission (EC) granted marketing authorization for EVENITY for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. For Otezla, the company expects data from the Phase 3 study in patients with mild-to-moderate psoriasis by mid-year 2020.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

SBUX Earnings: Key quarterly highlights from Starbucks’ Q4 2024 financial results

Starbucks Corporation (NASDAQ: SBUX) reported its fourth quarter 2024 earnings results today. Consolidated net revenues declined 3%, including on a constant currency basis, to $9.1 billion compared to the same

Key highlights from Biogen’s (BIIB) Q3 2024 earnings results

Biogen Inc. (NASDAQ: BIIB) reported its third quarter 2024 earnings results today. Total revenue decreased 3% year-over-year to $2.46 billion. Revenues were down 3% on a constant currency basis as

Infographic: Caterpillar (CAT) reports lower Q3 revenue and adj. profit

Caterpillar Inc. (NYSE: CAT), a leading manufacturer of construction and mining equipment, on Wednesday reported a decrease in revenue and adjusted earnings for the third quarter of 2024. Sales and

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top